Krystal Biotech, Inc. is a pharmaceutical company based in the United States, specializing in the development of redosable gene therapies for patients with rare dermatological diseases. With a high ESG risk rating score of 32.1, Krystal Biotech is committed to sustainability and good governance practices in the healthcare sector. Using its innovative gene therapy platform, STAR-D, the company aims to improve the lives of patients by treating conditions caused by genetic mutations. With a focus on dermatological indications, Krystal Biotech plans to expand its pipeline in the future, demonstrating its dedication to environmental and social responsibility.